Microsoft, Google invest in genomics platform firm DNAnexus

Foresite Capital, Microsoft, GV and others invested $58 million in genomics firm DNAnexus.

Biopharma companies, medical research institutions and healthcare facilities have growing interest in getting more genomics data, and that has translated into new investments. A $58 million financing round DNAnexus completed is just one recent example.

The round was led by healthcare-focused investment firm Foresite Capital, with strategic investment from Microsoft. Alphabet’s investment arm GV (formerly Google Ventures) and Wuxi AppTec’s genomics subsidiary WuXi NextCODE are among existing investors that also participated.

The California company’s cloud-based platform enables sharing, management and analysis of huge volumes of genomic data to help researchers collaborate on R&D projects.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

“As the volume of biomedical information continues to increase, the DNAnexus platform and upcoming product releases catalyze collaboration, data sharing and machine learning on which the development of precision medicine depends,” Foresite founder and CEO Jim Tananbaum said in a statement.

To DNAnexus CEO Richard Daly, such cross-institutional collaborations are crucial in creating multi-omics data that aid biomedical insights. The $58 million—a large infusion compared with the $15 million it raised back in 2014 and another $15 million it got from WuXi in 2015—will be used on further development and launch of its translational medicine solutions, as well as expanding the reach of its platform in clinical trials, said Daly.

DNAnexus has made quite a few high-profile expansions in the drug R&D market in 2017.

Its platform was chosen by AstraZeneca’s Centre for Genomics Research, a project launched in 2016 through a partnership with Craig Venter’s Human Longevity, to analyze over two million genomes in a decade to inform drug discovery and development.

RELATED: AstraZeneca teams with Venter to mine genomes for R&D insights

In June, it launched a new microbiome platform called Mosaic in collaboration with Janssen Research & Development. The idea is quite the same, that scientists could store and manage microbiome data securely and collaborate easily.

A few weeks ago, DNAnexus started incorporating Google’s new DeepVariant bioinformatics technology on its platform. The Google-developed tool uses deep learning to call genetic variants from next-generation sequencing data.

“DeepVariant is one of the first tools to deliver on that promise by making the critical first step to more accurately identify genetic differences among individuals,” Vik Bajaj, Foresite’s managing director and former CSO at Verily Life Sciences, said in a statement back then. “By making a reference implementation broadly accessible, I believe Google and DNAnexus will accelerate a growing body of research that requires high-quality genomic information.”

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.